TASE management joined by the management of the newest constituents to the TA-100 index opened trade on the morning of December 16, 2012.
4 of the 6 companies joining the index are "biomed" companies.
Photographed (from left to right) : Dr. Anat Cohen-Dayag, CEO Compugen; Ofer Haviv, CEO Evogene; Ester Levanon, CEO TASE; Zami Aberman, CEO Pluristem Therapeutics, David Tsur, CEO Kamada; and Alex Lifshitz, Senior Executive Ashtrom Properties
Photograph: Israel Malovani